Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

8.910 -0.960 (-9.73%)

Streaming Delayed Price Updated: 1:54 PM EST, Dec 2, 2025 Add to My Watchlist

Price and Volume

Volume	406,096
Open	9.920
Bid (Size)	8.910 (300)
Ask (Size)	8.920 (500)
Prev. Close	9.870
Today's Range	8.910 - 10.22
52wk Range	2.315 - 12.19
Shares Outstanding	61,758,994
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Today 8:30 EST

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Performance

YTD	+84.1%	+84.1%
1 Month	-1.2%	-1.2%
3 Month	+39.0%	+39.0%
6 Month	+28.0%	+28.0%
1 Year	+129.6%	+129.6%

More News

Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 18, 2025

Via Benzinga

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

November 03, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

October 29, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 23, 2025

Via Benzinga

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

October 22, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

October 14, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 25, 2025

Via Benzinga

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

August 26, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Small-Cap Stocks: An Undervalued Opportunity in a Cautious Market?

August 21, 2025

Via MarketMinute

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 08, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 30, 2025

Via Benzinga

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

July 29, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

July 29, 2025

Via Benzinga

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

July 29, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

July 28, 2025

Via Chartmill

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

July 28, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?

Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?

The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market

What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?

The current price of Fulcrum Therapeutics, Inc. - Common Stock is 8.910

When was Fulcrum Therapeutics, Inc. - Common Stock last traded?

The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 12/02/25 01:54 PM ET

What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?

The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 550.27M

How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?

Fulcrum Therapeutics, Inc. - Common Stock has 550M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.